Dysregulation of the oncogenic transcription factor MYC induces B-cell transformation and is a driver for B-cell non-Hodgkin lymphoma (B-NHL). MYC overexpression in B-NHL is associated with more aggressive phenotypes and poor prognosis. Although genomic studies suggest a link between MYC overexpression and B-cell receptor (BCR) signaling molecules in B-NHL, signaling pathways essential to Myc-mediated B-cell transformation have not been fully elucidated. We utilized intracellular phospho-flow cytometry to investigate the relationship between Myc and BCR signaling in pre-malignant B cells. Utilizing the Eμ-myc mouse model, where Myc is overexpressed specifically in B cells, both basal and stimulated BCR signaling were increased in precancerous B lymphocytes from Eμ-myc mice compared with wild-type littermates. B cells overexpressing Myc displayed constitutively higher levels of activated CD79α, Btk, Plcγ2 and Erk1/2. Notably, Myc-overexpressing B cells maintained elevated BCR signaling despite treatment with ibrutinib, a Bruton's tyrosine kinase inhibitor. Furthermore, PI3K/Akt pathway signaling was also increased in Eμ-myc B cells, and this increase was partially suppressed with ibrutinib. In addition, experiments with Btk-null B cells revealed off-target effects of ibrutinib on BCR signaling. Our data show that in pre-malignant B cells, Myc overexpression is sufficient to activate BCR and PI3K/Akt signaling pathways and further enhances signaling following BCR ligation. Therefore, our results indicate that precancerous B cells have already acquired enhanced survival and growth capabilities before transformation, and that elevated MYC levels confer resistance to pharmacologic inhibitors of BCR signaling, which has significant implications for B-NHL treatment.
INTRODUCTION
Non-Hodgkin lymphoma (NHL) represents a spectrum of morphologically, phenotypically and genetically distinct lymphomas with~85% of B-lymphocyte lineage. Overexpression of the oncogenic transcription factor MYC is associated with an aggressive phenotype and poor overall survival, regardless of the B-NHL subtype. [1] [2] [3] [4] Dysregulated Myc expression in primary murine B cells drives cellular transformation and lymphomagenesis and is necessary for both human and murine lymphoma maintenance. [5] [6] [7] Signaling through the B-cell receptor (BCR) in the absence of antigenic stimulation is important for normal B-cell differentiation and survival. 8, 9 In addition, ligation of the BCR induces a cascade of phosphorylation events and activation of multiple kinases, including the spleen tyrosine kinase (SYK) and Bruton's tyrosine kinase (BTK), leading to MAPK and NF-κB activation and a gene expression signature enriched for MYC-induced genes. [10] [11] [12] Independently of BTK, SYK can activate an alternative prosurvival pathway through PI3K/AKT. 13 Aberrant or chronic BCR signaling is commonly observed in B-NHL and contributes to lymphoma growth and survival, but the mechanisms for this remain incompletely understood. [14] [15] [16] Targeting the BCR pathway by silencing signaling proteins has deleterious effects on lymphoma cells with chronic BCR activation, 14 and pharmacologic inhibition of BTK by ibrutinib has shown encouraging results in the treatment of relapsed/refractory B-NHL. [17] [18] [19] Recent studies in human lymphoma cell lines identified components of the BCR pathway as possible MYC transcriptional targets. 20 In addition, the MYC-regulated miRNA cistron miR-17~92 was reported to influence BCR signaling in lymphoma cell lines. 21 Although these studies suggest a link between MYC overexpression and BCR signaling in lymphoma, the relationship between MYC and BCR signaling in non-transformed B lymphocytes was unknown. Therefore, we investigated BCR signaling in pre-malignant B cells. We determined that the levels of activated forms of multiple components of the BCR signaling pathway were increased both at rest and following ligation of the BCR in primary B cells overexpressing Myc. Myc-overexpressing B cells were less sensitive to Btk inhibition by ibrutinib, and off-target effects of ibrutinib were also identified. These studies highlight the relationship between Myc overexpression and pro-survival signaling, identify a means by which Myc drives lymphomagenesis, and provide insight into treatment strategies for patients with lymphoma expressing high levels of MYC protein.
RESULTS

Myc overexpression increases basal and stimulated BCR signaling in primary B cells
To investigate the influence of Myc on BCR signaling before cellular transformation, the spleens were harvested from Eμ-myc transgenic mice, which overexpress Myc specifically in B cells 5 ( Supplementary Figure 1) , before the development of lymphoma.
The spleens from wild-type littermates served as controls. Basal activity of BCR signaling proteins was interrogated in IgM + , CD19 + splenic B cells by intracellular phospho-flow cytometry (schematic Figure 1a ). Unstimulated B lymphocytes from Eμ-myc mice demonstrated significantly increased levels of phospho-Btk (36% elevated, P = 0.0179), phospho-Plcγ2 (48 and 40% elevated at Y759 and Y1217, P = 0.0013 and 0.0050, respectively) and phospho-Erk1/2 (56% elevated, P = 0.0007) compared with wild-type B cells ( Figure 1b ). Levels of phospho-CD79α and phospho-Syk were also increased in unstimulated Eμ-myc splenic B cells (28 and 9% elevated, respectively; Figure 1b ), but differences did not reach statistical significance (P = 0.07 and P = 0.12, respectively). Therefore, Myc overexpression alone increased basal signaling of several proteins in the BCR pathway in primary, non-transformed B cells.
Ligation of the BCR activates signaling of the pathway above basal levels. 22 To determine whether Myc expression affects activated BCR signaling, we ligated the BCR with anti-IgM F(ab′) 2 . At intervals after BCR ligation, proteins in the BCR pathway were evaluated by intracellular phospho-flow cytometry. We detected robust activation of proteins that are activated early following IgM ligation (for example, CD79α, Syk, Btk and Plcγ2) in both Eμ-myc and wild-type splenic B cells ( Figure 1c ). Although the activation curves were similar in Eμ-myc and wild-type cells, with two-to fourfold increases in each phospho-protein following ligation of the BCR, there were notable differences. Specifically, although basal levels of activated CD79α were statistically equivalent in Eμmyc and wild-type B cells, there was a sharp increase in phospho-CD79α in Eμ-myc cells that significantly exceeded that of wild-type cells at 5 (P = 0.0041), 10 (P = 0.0115), 30 (P = 0.0065) and 60 min (P = 0.0055) following BCR ligation (upper left, Figure 1c ). Phospho-CD79α peaked within 30 min in Eμ-myc B cells at a level 2.8-fold above the baseline. In contrast, phospho-CD79α peaked later in wild-type B cells, achieving a level 2.6-fold above baseline 60 min after BCR ligation (upper left, Figure 1c ). In addition, although activation of Syk in Eμ-myc B cells paralleled that of wild-type B cells (middle left, Figure 1c ), the levels of activated downstream proteins phospho-Btk (bottom left, Figure 1c ) and phospho-Plcγ2 (Y1217) (middle right, Figure 1c ) started and remained significantly higher in Eμ-myc B cells over 60 min after BCR ligation. Levels of phospho-Plcγ2 (Y759) were slightly higher in Eμ-myc cells until 30 min following BCR ligation and then decreased at a faster rate than wild-type cells (upper right, Figure 1c ). Together these data indicate that Myc overexpression altered the activation of Although phospho-Erk1/2 levels in Eμ-myc B cells were constitutively higher (52-81% higher) than in wild-type cells, we did not detect an expected increase in phospho-Erk levels following BCR ligation in either genotype (bottom right, Figure 1c ). Other known BCR downstream effector proteins, including NF-κB and p38MAPK, exhibited similar results (Supplementary Figure 2 ). Because multiple signals converge on downstream effector proteins, we postulated their activation is likely to be tightly regulated by phosphatases and thus, more difficult to detect. To further investigate Erk phosphorylation, we added hydrogen peroxide (H 2 O 2 ) after BCR ligation to transiently inactivate protein tyrosine phosphatases and allow the accumulation of phosphorylated Erk. Phospho-Erk1/2 levels increased nearly fivefold in both Eμ-myc and wild-type splenic B cells 10 min after BCR ligation and addition of H 2 O 2 (top left, Figure 2a ). Phosphatases typically recover from H 2 O 2 inactivation resulting in reduced phospho-protein levels by 30 min. 23 However, we observed in repeated experiments that phospho-Erk1/2 levels in Eμ-myc B cells declined more slowly compared with wild-type B cells in the presence of H 2 O 2 , remaining above baseline and nearly 50% higher than wild-type levels 30 min after BCR ligation. Therefore, Erk1/2 activity is differentially regulated in B cells that overexpress Myc, resulting in constitutively higher phospho-Erk1/2 levels and sustained signaling following BCR ligation.
We also evaluated other proteins in the BCR signaling pathway in the presence of H 2 O 2 . The addition of H 2 O 2 alone caused minimal accumulation of phosphorylated proteins in either genotype. However, following BCR ligation, H 2 O 2 augmented activation of CD79α, Syk, Btk and Plcγ2, which peaked by 10 min and returned to near baseline levels by 30 min in both genotypes, and again levels were significantly higher in Eμ-myc B cells. For example, following BCR ligation and addition of H 2 O 2 , phospho-CD79α and phospho-Plcγ2 (Y759) levels in Eμ-myc B cells increased 10-and 11-fold, respectively, as compared with sevenand ninefold in wild-type B cells and resulted in significantly higher peak phospho-protein levels at 10 min (P = 0.0013 for CD79α and P = 0.0150 for Plcγ2 (Y759); middle, Figure 2a ). Although phospho-Syk and phospho-Plcγ2 (Y1217) levels increased fiveand sevenfold, respectively, in B cells of both genotypes 10 min after BCR ligation and addition of H 2 O 2 (bottom, Figure 2a ), peak phospho-protein levels were significantly higher in Eμ-myc B cells compared with wild-type (P = 0.0012 for Syk and P = 0.0154 for Plcγ2 (Y1217)). In addition, the phospho-Btk levels were significantly higher in Eμ-myc cells (P = 0.0001) 10 min after BCR ligation and H 2 O 2 addition (upper right, Figure 2a ), even though phospho-Btk increased nearly 25-fold in wild-type B cells compared with 11-fold in Eμ-myc cells. Histograms of fluorescence in B cells from a representative experiment illustrate increased phospho-protein levels 10 min after BCR ligation and/or H 2 O 2 addition by a shift of the curves to the right and return toward baseline by 30 min (Figure 2b ). These data provide additional evidence that untransformed Myc-overexpressing B cells have increased basal BCR signaling and that Myc further increases BCR signaling following receptor ligation. 
Eμ-myc splenic B cells exhibit resistance to Btk inhibition
Following BCR ligation, Syk phosphorylates tyrosine-551 of Btk, which prompts autophosphorylation of tyrosine-223 in Btk. 24 Ibrutinib covalently binds Btk near the ATP-binding domain to irreversibly inhibit Btk activity. 25 Given the robust activation of Btk in Eμ-myc B lymphocytes following BCR ligation, we postulated ibrutinib would be a potent inhibitor of Btk activation in B cells that overexpressed Myc. We first evaluated basal levels of phospho-Btk (Y223) in splenic B cells treated with increasing concentrations of ibrutinib. Treatment with ibrutinib induced equivalent dose-dependent decreases in basal levels of phospho-Btk in wild-type and Eμ-myc B cells (Figure 3a) , with a 38% decrease using 12.5 μM ibrutinib and a 58% decrease with 62.5 μM ibrutinib. After BCR stimulation, there was a greater reduction in phospho-Btk levels in Eμ-myc B cells compared with wild-type cells, with 12.5 μM ibrutinib achieving 42% reduction in phospho-Btk in Eμ-myc B cells, but only 26% reduction in wild-type cells (Figure 3b ). Nevertheless, absolute levels of phospho-Btk remained higher in Eμ-myc B cells than in wild-type cells over the range of ibrutinib concentrations (Figure 3b) . Notably, the level of phospho-Btk in 12.5 μM ibrutinib-treated Eμ-myc B lymphocytes was analogous to the level of phospho-Btk in untreated wild-type cells 10 min after BCR ligation (P = 0.54; Figure 3b ).
We also investigated downstream of Btk by assessing basal and BCR-stimulated levels of phospho-Plcγ2 (Y759) and phospho-Erk1/2 in the presence of ibrutinib. Ibrutinib treatment led to dosedependent decreases in phospho-Plcγ2 (Y759) in unstimulated B cells and B cells after BCR ligation ( Supplementary Figures 3A and  B ). Ibrutinib did not affect basal levels of phospho-Erk (T203/Y205) even in the presence of H 2 O 2 (Supplementary Figure 3C ), but potently reduced stimulated phospho-Erk levels (Supplementary Figure 3D ). Importantly, at any concentration of ibrutinib, levels of phospho-Btk, phospho-Plcγ2 and phospho-Erk remained higher in Eμ-myc B cells than in wild type. Therefore, Myc overexpression renders B cells relatively resistant to Btk inhibition by ibrutinib.
Based on its mechanism of action and reported specificity for Btk inhibition, 25 we expected ibrutinib would inhibit Btk phosphorylation and consequently, phosphorylation of downstream components of BCR signaling (for example, Plcγ2 and Erk1/2; Figure 1a ). Although treatment with ibrutinib (12.5 μM) reduced phospho-Btk levels in IgM-ligated Eμ-myc B cells by 47%, these levels were equivalent to the IgM-stimulated phospho-Btk levels in wild-type B cells that were not treated with ibrutinib (MFI 255 versus 194, respectively, P = 0.11; Figure 4a , third bar versus last bar). Ibrutinib (12.5 μM) had little effect on basal levels of phospho-Plcγ2 (Y759) in both genotypes (Figure 4b , 0 min dimethyl sulfoxide (DMSO) versus 0 min ibrutinib). However, the levels of phospho-Plcγ2 (Y759) after BCR ligation remained~50% higher in ibrutinib-treated Eμ-myc B cells than ibrutinib-treated wild-type cells (MFI 93 versus 60, respectively, P = 0.0016, Figure 4b last two bars), and this level in ibrutinib-treated Eμmyc B cells was analogous to the level of phospho-Plcγ2 (Y759) in IgM-stimulated wild-type B cells that had not been treated with ibrutinib (MFI 95, P = 0.42; Figure 4b , third bar versus last bar). Absolute levels of phospho-Erk and phospho-Plcγ2 (Y1217) were significantly higher in Eμ-myc B cells than in wild-type B cells, but we did not detect an increase in activation following BCR ligation or an effect of ibrutinib in the absence of H 2 O 2 (Figure 4c and Supplementary Figure 4A , respectively).
We again utilized H 2 O 2 to better visualize the effects of ibrutinib on phospho-Erk1/2. As we observed previously with addition of H 2 O 2 , Erk1/2 activation was detectable 10 min after BCR ligation and persisted in Eμ-myc cells beyond that in wild-type cells (Figure 4d ). Treatment with ibrutinib attenuated activation of Erk1/2 in both genotypes, but phospho-Erk1/2 levels remained higher in the Eμ-myc B cells at every time evaluated (Figures 4d, P = 0.0008, 0.0522 and 0.0413 at 0, 10 and 30 min, respectively). H 2 O 2 also accentuated the differences between Eμ-myc and wildtype B cells following ibrutinib treatment when evaluating Plcγ2. Phospho-Plcγ2 (Y759) in ibrutinib-treated Eμ-myc B cells was 1.3fold and 4.2-fold greater than in ibrutinib-treated wild-type cells at 10 and 30 min, respectively, after BCR ligation and addition of H 2 O 2 (P = 0.0201 and P = 0.0013, respectively, Figure 4e ). The absolute levels of phospho-Plcγ2 (Y759) in ibrutinib-treated Eμmyc B cells were statistically equivalent to levels in wild-type cells that were not treated with ibrutinib (MFI: 116 000 and 113 250, respectively, at 10 min, P = 0.39; MFI: 34 402 and 31 520, respectively, at 30 min, P = 0.28; Figure 4e , dashed line with square symbol versus solid line with circle symbol). Levels of phospho-Plcγ2 (Y1217) also remained higher in Eμ-myc cells than in wildtype B cells despite ibrutinib treatment (Supplementary Figure 4B) . Thus, as predicted, ibrutinib blunted the phosphorylation of Plcγ2 and Erk1/2; however, more complete inhibition was evident in the wild-type B cells.
Ibrutinib has off-target effects on other kinases
We also evaluated the effect of ibrutinib on the BCR pathway upstream of Btk (Figure 1a ), originally as a negative control, as ibrutinib is a Btk-specific inhibitor and should not alter signaling upstream of Btk. 25 Unexpectedly, in both wild-type and Eμ-myc B cells, CD79α and Syk phosphorylation was also inhibited by ibrutinib (Figures 5a and b) . There was little effect on the basal levels of phospho-CD79α with ibrutinib treatment (Figure 5a , first two bars versus fifth and sixth bars), but a pronounced reduction was evident in BCR-stimulated cells (∼30% reduction in both genotypes; Figure 5a , second and third bars versus last two bars). As with Btk, BCR-stimulated phospho-CD79α levels were similar in ibrutinib-treated Eμ-myc B cells and wild-type B cells that were not ibrutinib-treated (Figure 5a , third bar versus last bar, P = 0.506). Treatment with ibrutinib (12.5 μM) reduced basal and BCRstimulated phospho-Syk levels in both genotypes, with a 48% reduction in phospho-Syk levels in wild-type cells and a 34% decrease in Eμ-myc cells 30 min after BCR ligation (Figure 5b , third bar versus seventh bar and fourth bar versus last bar, respectively). Dose titration experiments indicated that even 0.0025 μM ibrutinib caused significant reductions in basal phospho-Syk in wild-type (9.3% reduction, P = 0.0263) and Eμ-myc B cells (10.3% reduction, P = 0.0188; Supplementary Figure 5A ). Higher concentrations of ibrutinib (0.25 μM for wild-type, P = 0.1367 and 0.03125 μM for Eμ-myc, P = 0.0044) were required to achieve 10% reductions in phospho-Syk after BCR ligation (Supplementary Figure 5B) . These data indicate that ibrutinib treatment inhibits more than just Btk activation in B cells.
To determine whether ibrutinib inhibits phosphorylation of CD79α and Syk directly or by a feedback loop with Btk or downstream effector molecules, we first evaluated total Btk levels in wild-type B cells after ibrutinib treatment. Ibrutinib treatment did not alter the total Btk levels in B cells (top panel, Figure 5c ). We also evaluated B cells from Btk-null mice, which do not express Btk protein 26, 27 (Figure 5c, top panel) . In BCR ligated Btk −/− B cells, ibrutinib treatment did not affect phosphorylation of CD79α (middle panel, Figure 5c ), whereas there was significantly reduced phosphorylation of Syk (bottom panel, Figure 5c ). Interestingly, the levels of activated CD79α and Syk following BCR ligation were significantly higher in Btk −/− B cells than wild-type B-cell controls. In addition, Btk −/− B cells were more sensitive to Syk inhibition by ibrutinib than wild-type B cells, as evidenced by a 26% reduction in phospho-Syk 10 min after ligation of the BCR in ibrutinibtreated Btk −/− B cells but only 11% reduction in phospho-Syk levels in wild-type B cells (P = 0.0015). In addition, dose-dependent decreases in phospho-Syk levels in Btk −/− B cells were similar to wild-type and Eμ-myc B cells (Supplementary Figure 6A ). Finally, Myc levels were evaluated in wild-type and Eμ-myc B cells and shown to not be affected by ibrutinib treatment in either genotype (Supplementary Figure 6B) , indicating the inhibition of signaling upstream of Btk by ibrutinib was not due to a reduction in Myc. Together these results imply that direct off-target effects are likely responsible for the reduction in phospho-Syk detected in B cells treated with ibrutinib.
Activation of BCR signaling by Myc overexpression induces Akt and ribosomal S6 kinases
The PI3K/Akt pathway is activated following ligation of the BCR by cross talk with kinases such as Syk (Figure 1a ). 13 Thus, we evaluated the effect of Myc overexpression on activation of Akt and ribosomal S6 kinases by evaluating phosphorylation of threonine-308 and serine-473 of Akt and ribosomal protein S6 (S6RP), respectively. In both Eμ-myc and wild-type B cells, small increases in phospho-Akt (T308) occurred quickly following BCR ligation (left panel, Figure 6a ), and returned to baseline within 30 min, whereas no significant changes were detected in phospho-Akt (S473; middle panel, Figure 6a ). Notably, the levels of phospho-Akt (T308 and S473) were constitutively higher in Eμmyc B cells compared with wild-type B cells (Figure 6a ). Following ligation of the BCR, phosphorylation of S6RP increased similarly in Eμ-myc and wild-type B cells over 60 min (right panel, Figure 6a ), but diverged by 180 min, when higher levels of phospho-S6RP were detected in Eμ-myc B cells compared with wild-type cells (P = 0.0562). Although H 2 O 2 has little direct effect on serine/ threonine phosphatases, it can indirectly impact them through upstream tyrosine kinases; 28 consequently, we evaluated both phospho-Akt sites following addition of H 2 O 2 . The addition of H 2 O 2 immediately after BCR ligation further accentuated the early increase in phospho-Akt (T308; left panel, Figure 6b ) and revealed a BCR ligation-induced increase in phospho-Akt (S473) that was not evident in the absence of H 2 O 2 (middle panel, Figure 6b ). H 2 O 2 had minimal effect on detection of phospho-S6RP in wild-type B cells, but allowed a slight accumulation of phospho-S6RP in Eμmyc cells (right panel, Figure 6b ), suggesting altered regulation of S6 kinases in Myc-overexpressing cells.
We also assessed whether ibrutinib affected Akt phosphorylation. Treatment with ibrutinib reduced basal and BCR-stimulated phospho-Akt (T308) in Eμ-myc and wild-type B cells, but absolute levels were higher in ibrutinib-treated Eμ-myc cells than in untreated wild-type cells (left upper panel, Figure 6c ). On exposure to H 2 O 2 , proportionally larger reductions in phospho-Akt (T308) occurred in ibrutinib-treated Eμ-myc B cells, but again the levels remained higher in ibrutinib-treated Eμ-myc cells compared to wild-type cells that were not treated with ibrutinib (left lower panel, Figure 6c ). Phosphorylation of Akt (S473) was not affected by ibrutinib treatment in either genotype in the absence or presence of H 2 O 2 (upper and lower middle panels, Figure 6c ). Ibrutinib treatment significantly inhibited basal and BCR-stimulated phosphorylation of S6RP in both Eμ-myc and wild-type B cells in the absence (upper right panel, Figure 6c ) and presence (lower right panel, Figure 6c ) of H 2 O 2 . Again, phospho-S6RP levels remained higher in ibrutinib-treated Eμ-myc cells than wild-type B cells and were similar to levels in untreated wild-type B cells. Together, these data indicate that Myc overexpression activates PI3K/Akt signaling and that ibrutinib has previously unappreciated effects beyond Btk inhibition.
DISCUSSION
Myc is required for the growth and survival of B-cell lymphomas, and its overexpression is frequently selected for in these malignancies. 7 Genetically engineered mice showed that Myc overexpression induces B-cell transformation, solidifying Myc as a driver of B-cell lymphoma. 5 However, the cellular mechanisms by which Myc dysregulation induces B-cell transformation had not been fully explored. Our study focused on cell signaling and revealed that before cellular transformation, Myc overexpression alone led to increased signaling through pro-growth and survival pathways, including the BCR and PI3K/Akt pathways. There was significantly increased basal activation of Btk, Plcγ2, Erk1/2 and Akt in non-transformed, primary splenic B cells from Eμ-myc mice compared with wild-type littermates. Moreover, our data show these Myc-mediated increases in signaling cannot be fully inhibited with ibrutinib, which has clinical implications.
Ligation of the BCR prompts phosphorylation of downstream kinases and effector molecules, such as Syk, Btk, Plcγ2 and Erk1/2, as well as components of the PI3K/Akt pathway in normal B lymphocytes (Figure 1a ). Following BCR ligation in B cells from Eμ-myc mice, we detected more robust activation of CD79α, Btk and Plcγ2. In addition, levels of phospho-Erk1/2 and phospho-Akt were constitutively higher in B cells from Eμ-myc mice. Increased BCR signaling is reported to contribute to B-cell lymphoma development. 29 Finally, as evidenced by increased levels of phospho-S6RP 180 min after BCR ligation, Myc overexpression led to sustained activity of ribosomal S6 kinases, which are important regulators of cell growth and metabolism.
Although we detected high levels of activated Erk1/2 and p38MAPK in B cells from Eμ-myc mice, we were unable to detect further activation in either genotype following BCR ligation. Consequently, we utilized H 2 O 2 , which allowed phosphorylated proteins to accumulate, and as such, we were able to detect BCRinduced increases in phospho-Erk and phospho-p38MAPK, implying these kinases are tightly regulated. Although phosphatases that regulate upstream proteins in the BCR pathway had rebounded by 30 min after H 2 O 2 addition, phospho-Erk1/2 levels remained elevated, suggesting phosphatases that regulate Erk activation are more sensitive to H 2 O 2 inhibition. Furthermore, altered regulation of Erk1/2 activation in Eμ-myc B cells allowed for higher basal and more sustained BCR-stimulated Erk signaling. The levels of phospho-p38MAPK were also higher in Eμ-myc B cells compared with wild-type. These results are consistent with our previous report that Myc overexpression was sufficient to induce Ras/MAPK signaling. 30 Together these data indicate Erk1/2 and p38MAPK are involved in BCR signaling and are regulated by mechanisms that are different than upstream kinases.
Activation of BCR signaling leads to a transcriptional program that is enriched for MYC and MYC-induced genes. 10, 11 In addition, genomic studies in Burkitt lymphoma cell lines identified CD79β and SYK as potential transcriptional targets of MYC, 20 and the MYC-regulated miR-17~92 cluster augments signaling through the BCR in transformed lymphoma cells. 21 These reports together with our data suggest a feed-forward loop, whereby MYC expression increases BCR signaling, which further amplifies MYC activation, and so on. Importantly, our data indicate that such a feed-forward mechanism is not dependent on oncogenic transformation, as Myc overexpression alone augmented both basal and stimulated signaling by multiple proteins in the BCR signaling cascade in non-transformed B cells. Aberrant activation of BCR and PI3K/Akt signaling has been demonstrated in B-NHL. Prolonged or continuous signaling via the BCR pathway and reduced sensitivity to negative regulation have been identified in various lymphoid malignancies. 14, 16, 31, 32 Our data indicate that elevated Myc levels likely contribute to this increased signaling. Moreover, as inhibition of BCR activation in vitro by genetic or pharmacologic means has proven deleterious to lymphoma growth and survival, 14, 16, 33, 34 pharmacologic inhibition has been an attractive prospect for drug development. Indeed, ibrutinib is efficacious in the treatment of indolent B-NHL; [17] [18] [19] however, a subset is refractory to ibrutinib. We determined that hyperactivation of BCR signaling by Myc confers relative resistance to Btk inhibition by ibrutinib. Although ibrutinib did reduce phosphorylation and activation of Btk in Mycoverexpressing B cells, absolute levels of activated Btk and downstream proteins Plcγ2 and Erk1/2 remained higher following ibrutinib treatment than the levels in untreated wild-type B cells. Our studies predict that B-NHL with increased MYC expression may be less likely to respond to ibrutinib specifically and possibly BCR inhibition more generally. Although MYC expression in indolent lymphomas is not routinely evaluated, it may be worthwhile if ibrutinib treatment is being considered. Furthermore, although aberrant BCR signaling has been demonstrated in aggressive large cell lymphomas, ibrutinib therapy has not been as successful. 17 We postulate that differential responses to ibrutinib treatment may correlate with MYC expression, recognizing that MYC overexpression is associated with more aggressive lymphoma phenotypes.
We observed treatment with ibrutinib impaired the activation of Btk and downstream signaling molecules, but also reduced the activation of upstream signaling proteins CD79α, Syk and Akt in both Myc-overexpressing and wild-type B cells. These results were unexpected as ibrutinib is reported to be highly specific for Btk. 25, 35 Ibrutinib did not affect SYK phosphorylation in a previous report, but only tyrosine-352 was interrogated, 34 whereas SYK activation is complicated by phosphorylation of multiple tyrosine residues, the roles of which have not been fully elucidated. 36, 37 Nevertheless, tyrosine-352 is believed to lie in a regulatory domain, whereas tyrosine-525/526 are in the activation loop and are autophosphorylated upon ligation of the BCR, 37 and reportedly are better predictors of SYK activity in diffuse large B-cell lymphoma. 38 Therefore, we evaluated phosphorylation of the murine homologous residues, tyrosine-519/520. Data showed inhibition of Syk phosphorylation by ibrutinib occurred in Mycoverexpressing and wild-type B cells in a dose-dependent manner. This inhibition was also observed in Btk −/− B cells, indicating it is an off-target effect rather than the result of a regulatory feedback loop. Therefore, the ibrutinib-mediated reduction in phospho-Akt and phospho-S6RP that we detected may be secondary to Syk inhibition, as Syk activates PI3K/Akt signaling following BCR ligation. 13 These unexpected findings could provide an alternative explanation for the increased bleeding risk in patients treated with ibrutinib, which has been previously linked to ineffective collagenevoked signaling in platelets. 39, 40 Phosphorylation of SYK (Y525) is associated with platelet activation and thrombus formation in the setting of sheer stress. 41 Therefore, inhibition of SYK by ibrutinib may lead to ineffective thrombosis and bleeding.
Our results expand understanding of the role of Myc in cell signaling and indicate Myc overexpression alone is sufficient to cause aberrant activation of pro-growth and survival signaling that likely contributes to lymphomagenesis. Our data have significant clinical implications for targeting the BCR pathway in human lymphomas that highly express MYC. In addition, we showed offtarget effects of ibrutinib on Syk that may explain some side effects of ibrutinib therapy. Furthermore, the relative resistance to Btk inhibition by ibrutinib in cells that overexpress Myc suggest MYC expression may serve as a therapeutic biomarker.
MATERIALS AND METHODS Mice
Male C57Bl/6 Eμ-myc mice 5 were mated to C57Bl/6 females to generate transgenic and nontransgenic littermates. C57Bl/6 Btk −/− mice 26 and C57Bl/6 wild-type controls were provided by Dr Peggy Kendall (Vanderbilt University Medical Center). The spleens were harvested from mice 4-6 weeks of age before lymphoma development. All mouse studies were in accordance with state and federal guidelines and were approved by the Vanderbilt Institutional Animal Care and Use Committee.
Intracellular flow cytometry
The protocol was modified from Irish, et al. 42 Briefly, following disaggregation and red blood cells lysis, 1 × 10 7 splenocytes/ml in culture medium were incubated at 37C for 60 min. For assessment of upstream BCR signaling proteins, culture medium was DMEM+10% fetal bovine serum. For Erk, p38MAPK, Akt and S6RP assessment, fetal bovine serum was reduced to 2.5% for the 3 h kinetic experiments or 0% for shorter experiments. BCR signaling was stimulated by ligation of IgM with 10 μg/ml anti-mouse IgM F(ab′) 2 fragments (Jackson ImmunoResearch, West Grove, PA, USA). For some experiments, splenocytes were pretreated for 1 h with ibrutinib (Selleckchem, Houston, TX, USA) or dimethyl sulfoxide (control). In indicated experiments, H 2 O 2 (550 μM) was added immediately after BCR ligation. The cells were fixed with 1.5% paraformaldehyde (10 min, room temperature) at one time after intervals following IgM ligation. The cells were incubated with anti-IgM and anti-CD19 antibodies, permeabilized with 0.1% Triton-X (5 min, 4C), and then incubated with phospho-specific antibodies in phosphate-buffered saline, 3% fetal bovine serum, 15 mM sodium azide. In some cases, unconjugated phosphospecific antibodies were used, followed by AlexaFluor 647-conjugated goat anti-rabbit IgG (Cell Signaling Technology, Danvers, MA, USA) for 30 min at room temperature. For a list of antibodies used, see Supplementary Table  1 . Fluorescence was measured on a BD Fortessa flow cytometer, and data were analyzed with FlowJo software.
Statistics
Unless otherwise stated, values represent mean ± s.e.m., and paired t-test was used for comparisons.
